Skip to content
Search

Latest Stories

India's Aurobindo clarifies Zentiva buyout reports as ‘premature’

Prague-based Zentiva is a well-known producer of generic medicines across Europe.

India's Aurobindo clarifies Zentiva buyout reports as ‘premature’

FILE PHOTO: A pharmacist shows a box of Prednisolone by Zentiva in Brest, western France. -(FRED TANNEAU/AFP via Getty Images)

INDIA's Aurobindo Pharma on Wednesday (20) dismissed media reports suggesting it had finalised a deal to acquire Czech drugmaker Zentiva, calling the claims “premature” and added that no binding agreement has been signed.

The clarification came after The Economic Times reported that Aurobindo was the frontrunner to acquire Zentiva from US-based private equity firm Advent International in a deal valued between $5 billion and $5.5bn (around £3.95bn to £4.35bn). If confirmed, this would be the largest-ever overseas acquisition by an Indian pharmaceutical company.


However, Aurobindo issued a statement to stock exchanges denying that any agreement had been finalised.

“As part of our business strategy, the company regularly explores various strategic opportunities, including potential acquisitions and partnerships, which can enhance shareholder value,” Aurobindo Pharma said in a regulatory filing on Wednesday.

“But at present, no binding agreement or definitive decision has been made by the Board of Directors of the company in relation to the transaction referred to in the said article(s). Accordingly, the said news item is premature and should not be relied upon,” the company added.

Aurobindo also assured investors that it would make timely disclosures if any definitive development arises that requires notification under India's regulator, SEBI.

The company's shares fell as much as 4.7 per cent during early trading on Wednesday after the report was published, but recovered slightly following the clarification. The stock closed 3.9 per cent lower on the NSE. So far in 2025, Aurobindo Pharma’s stock has dropped around 21 per cent, compared to a two per cent rise in the benchmark Nifty 50 index.

Advent International and Zentiva have not commented on the report.

Zentiva, based in Prague, is a well-known producer of generic medicines across Europe. If Aurobindo were to go ahead with the acquisition, it would mark a major step in expanding its presence in the European market and diversifying its portfolio beyond the US.

The reported deal would surpass other significant transactions in the Indian pharma sector, including Sun Pharma’s acquisition of Ranbaxy and Biocon Biologics’ buyout of Viatris’ biosimilar business.

Aurobindo is already active in international expansion. In July, its wholly owned US subsidiary signed a deal to acquire Lannett Company LLC, a generics manufacturer, for about $276 million (£218m). That deal is aimed at strengthening its manufacturing base and product offerings in the US.

The US remains a crucial market for Aurobindo, contributing nearly half of its annual revenue. Industry analysts say Indian pharma firms are increasingly pursuing global acquisitions to mitigate risks from potential US trade policies. US president Donald Trump had recently suggested steep tariffs on imported medicines.

“We’ll be putting initially a small tariff on pharmaceuticals, but in one year – one and a half years, maximum – it’s going to go to 150 per cent and then it’s going to go to 250 per cent because we want pharmaceuticals made in our country," Trump said in an interview.

More For You

UK grocery inflation eases to 5 per cent in August

Britain’s food retailers have said that higher employer taxes and regulatory costs as well as increased staff wages are adding to inflationary pressure

iStock

UK grocery inflation eases to 5 per cent in August

British grocery inflation nudged down to stand at five per cent over the four weeks to 10 August, data from market researcher Worldpanel by Numerator showed on Tuesday (19), providing a little relief for consumers.

The figure, the most up-to-date snapshot of UK food inflation, compared with 5.2 per cent in last month’s report.

Keep ReadingShow less
Modi-Getty

In his Independence Day address, Modi said the goods and services tax (GST) would be reformed and rates lowered by Diwali, which falls in October. (Photo: Getty Images)

Getty images

India to slash consumption tax by October after Modi’s reform push

INDIA’s government will reduce consumption tax rates by October, a top official said on Friday, hours after prime minister Narendra Modi announced reforms to support the economy amid trade tensions with the United States.

The federal government is planning a two-rate structure of 5 per cent and 18 per cent, removing the existing 12 per cent and 28 per cent slabs, the official told Reuters, requesting anonymity as the plans are still under discussion.

Keep ReadingShow less
Morrisons CEO joins Gol Gappay eating contest to mark South Asian Heritage Month

CEO of Morrisons Rami Baitiéh (centre) takes on the Heera Foods Gol Gappay challenge

Morrisons CEO joins Gol Gappay eating contest to mark South Asian Heritage Month

Morrisons chief executive Rami Baitiéh took part in a lively “Gol Gappay Challenge” at the supermarket’s Bradford headquarters on Tuesday, as part of celebrations for South Asian Heritage Month.

The event, hosted in the company’s central atrium, was led by Bradford-based Heera Foods, which served up its popular Gol Gappay – crispy puris filled with spiced chickpeas and tangy water – to staff and visitors.

Keep ReadingShow less
Mounjaro

When Mounjaro was launched in Britain, Lilly set a list price 'significantly below' that in its other three European markets to avoid delays in NHS availability. (Photo: Reuters)

Lilly to raise UK Mounjaro price by 170 per cent from September

ELI LILLY said on Thursday it will increase the UK list price of its weight-loss drug Mounjaro by up to 170 per cent. The price change comes as the White House urges drugmakers to raise prices in Europe to enable price cuts in the United States.

The new price, which also applies to Lilly's type 2 diabetes medicine sold under the same name, will take effect in September. A month's supply of the highest dose will rise from £122 to £330, the company said.

Keep ReadingShow less
UK business district

The Canary Wharf business district including global financial institutions in London. (Photo: Getty Images)

Getty Images

UK economy grows more than expected in April-June quarter

UK's economy grew more than expected in the second quarter, though at a slower pace than the first three months of 2025, as US tariffs and a higher UK business tax weighed on activity, official data showed on Thursday.

Gross domestic product rose 0.3 per cent in April-June, the Office for National Statistics (ONS) said, above analyst forecasts of 0.1 per cent growth. This followed a 0.7 per cent rise in the first quarter.

Keep ReadingShow less